White House, Regeneron drug pricing deal

What's happening

The White House is set to announce a drug pricing agreement with Regeneron Pharmaceuticals today. As part of the "most-favored-nation" initiative, Regeneron will lower prices for current and future drugs on Medicaid and offer its cholesterol drug, Praluent, for $225 on the discounted drug website TrumpRx.

What's changing / Business impact

• Government is pushing direct pricing negotiations with pharma.
• Signals continued expansion of: price control mechanisms and negotiation frameworks.
• Pharma companies face increasing pressure on margins.

Why this matters

This shows:

• Policy is shifting from passive regulation → active negotiation.
• Pricing power is moving away from pharma toward government influence.
• Future revenue models will depend on policy alignment, not just innovation.